1.17
4.88%
-0.06
Handel nachbörslich:
1.23
0.06
+5.13%
Schlusskurs vom Vortag:
$1.23
Offen:
$1.22
24-Stunden-Volumen:
143.40K
Relative Volume:
0.46
Marktkapitalisierung:
$16.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.6714
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
-2.50%
1M Leistung:
-23.53%
6M Leistung:
-40.91%
1J Leistung:
+0.86%
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.17 | 16.93M | 0 | -8.29M | -6.47M | -0.70 |
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive financial news
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors UK
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors UK
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA
NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors UK
NanoViricides Engages CRO for Phase II Clinical Trial - Oil City Derrick
NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 - Proactive Investors Australia
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Oil City Derrick
NanoViricides CEO discusses NV-387’s broad spectrum promiseICYMI - Proactive Investors Australia
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats - Proactive Investors Australia
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - AccessWire
NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World
First US bird flu fatality raises alarms over mutations in H5N1 virus - Proactive Investors USA
NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment - Proactive Investors UK
NanoViricides, Inc. Files Quarterly ReportReports a Strong Cash Position Sufficient for Initial C - AOL
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors UK
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News
NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz
NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA
NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News
NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news
NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA
Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
NNVC - Insider Financial
Chronic Fatigue Syndrome Market Demand and Opportunities - openPR
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick
Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey
7 Best Nanotech Penny Stocks to Buy - Insider Monkey
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):